Monograph Details
|
|
Hematology
> Immune-mediated blood disorders
|
|
HYPERRHO S/D MINI-DOSE |
| Manufacturer |
|
Talecris Biotherapeutics, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Immune globulin. |
| Generic Name |
|
Rho(D) immune globulin human; 250 IU; per syringe; soln for IM inj.; preservative-free; latex-free. |
| Also |
|
• HYPERRHO S/D FULL DOSE
|
| Indications |
|
Prevention of isoimmunization of Rho(D) negative women during spontaneous or induced abortion of ≤12 weeks' gestation when mother is not sensitized to Rho(D) antigen and father is not known to be Rho(D) negative. |
| Children |
|
Not recommended. |
| Adults |
|
Postabortion or miscarriage of up to 12 weeks gestation: 1 syringe IM within 3hrs of spontaneous or induced abortion or within 72hrs following termination of pregnancy. |
| Contraindications |
|
Neonates. |
| Precautions |
|
Contains human plasma; monitor for possible infection transmission. IgA deficiency. Pregnancy (Cat.C). |
| Interactions |
|
Avoid live vaccines within 3 months. |
| Adverse Reactions |
|
Local or infusion reactions. |
| Extra Text |
|
Note: Report all infections suspected to be transmitted by HyperRHO S/D to (800) 520-2807. |
| How Supplied |
Full dose (Single-dose prefilled syringe)—1
Mini dose (Single-dose prefilled syringe)—10 |
|
|
|
|
